Skip to main content

Table 1 Clinical features of the patients enrolled in the study

From: A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy

Patient Gender Severity of reaction
Pre VIT (according to Müller)
Age (years) VIT duration (months) Follow-up duration (months) Total VIT dose (SQ-U ×106) Total VIT dose (mg) VIT supplier
N.G. M IV 60 61 53 4.51   Alk
T.G. M IV 33 58 182   5.9 DHS
P.G. M IV 49 59 122   4.7 DHS
C.G. F III 21 60 184   5.1 DHS
C.G. M III 45 59 36   5.7 DHS
C.G. M III 35 60 199   6.5 DHS
D.F.T. M IV 51 58 103 1.82   Alk
R.F. M IV 44 59 151 2.05   Alk
G.G. F III 39 73 41 4.41   Alk
C.M. F IV 37 61 38 2.18   Alk
D.M.S M III 54 61 36 4.44   Alk
I.N. M IV 54 63 36 2.36   Alk
A.A. M III 13 63 62 2.11   Alk
C.M. M IV 39 64 43 2.19   Alk
D.F. M IV 59 64 66   5.8 DHS
T.A. M IV 49 62 28   5.7 DHS
V.V. M IV 50 59 51   5.6 DHS
T.A. M III 46 60 44 2.57   Alk
S.S. F III 29 50 36 3.85   Alk
M.S. M III 52 64 56 1.71   Alk
M.A. F III 33 64 27 2.28   Alk
V.R. M IV 52 62 37   6.5 DHS
M.F. M IV 40 64 31   5.7 DHS
Mean    42.78 61.22 72.26 5.73 2.80  
SD    11.81 4.02 55.37 0.54 1.07  
  1. DHS Dome Hollister Stier, ALK ALK-Abellò